BR100 Increased By (0.27%)
BR30 Increased By (0.15%)
KSE100 Increased By (0.15%)
KSE30 Increased By (0.01%)
BECO 5.92 Decreased By ▼ -0.11 (-1.82%)
BML 57.31 Increased By ▲ 4.56 (8.64%)
BOP 34.09 Decreased By ▼ -0.16 (-0.47%)
CNERGY 8.20 Increased By ▲ 0.04 (0.49%)
DCL 12.15 Decreased By ▼ -0.19 (-1.54%)
FCCL 53.88 Decreased By ▼ -0.01 (-0.02%)
FCSC 5.25 Increased By ▲ 0.03 (0.57%)
FFL 18.01 Decreased By ▼ -0.02 (-0.11%)
FNEL 1.31 Increased By ▲ 0.01 (0.77%)
HUMNL 11.23 Increased By ▲ 0.23 (2.09%)
KEL 8.17 Increased By ▲ 0.06 (0.74%)
KOSM 5.47 Increased By ▲ 0.09 (1.67%)
MLCF 88.79 Increased By ▲ 0.74 (0.84%)
NBP 186.50 Increased By ▲ 0.02 (0.01%)
PACE 10.96 Increased By ▲ 0.24 (2.24%)
PAEL 40.42 Increased By ▲ 0.48 (1.2%)
PIAHCLA 26.26 Increased By ▲ 0.09 (0.34%)
PIBTL 17.33 Increased By ▲ 0.01 (0.06%)
PPL 232.00 Decreased By ▼ -0.78 (-0.34%)
PRL 34.70 Decreased By ▼ -0.25 (-0.72%)
PTC 66.80 Decreased By ▼ -0.76 (-1.12%)
SEARL 91.45 Increased By ▲ 0.52 (0.57%)
SSGC 27.15 Decreased By ▼ -0.02 (-0.07%)
TELE 8.70 Increased By ▲ 0.13 (1.52%)
THCCL 65.35 Increased By ▲ 5.22 (8.68%)
TPLP 9.20 Increased By ▲ 0.44 (5.02%)
TREET 24.55 Increased By ▲ 0.01 (0.04%)
TRG 72.63 Increased By ▲ 0.88 (1.23%)
WAVES 10.70 Increased By ▲ 0.72 (7.21%)
WTL 1.26 No Change ▼ 0.00 (0%)
Business & Finance

Russia's Sputnik V developers to sue Brazilian regulator for 'false information' about their vaccine

  • The board of Brazilian health regulator on Monday rejected importing Sputnik V after technical staff warned of flaws in its development along with incomplete data regarding the vaccine's safety and efficacy.
  • A crucial issue for the Brazilian regulator was the risk of other viruses used to make the vaccine reproducing in patients, which an Anvisa expert had called a "serious" defect.
Published April 29, 2021 Updated April 29, 2021 07:46pm
By

MOSCOW: Russian developers of the Sputnik V vaccine against COVID-19 said on Thursday that they were suing Brazilian regulator Anvisa for defamation, accusing it of having knowingly spread false information without testing their product.

The board of Brazilian health regulator on Monday rejected importing Sputnik V after technical staff warned of flaws in its development along with incomplete data regarding the vaccine's safety and efficacy.

A crucial issue for the Brazilian regulator was the risk of other viruses used to make the vaccine reproducing in patients, which an Anvisa expert had called a "serious" defect.

Sputnik V's official Twitter account on Thursday cited a Brazilian media story citing the same expert as saying that no tests had been carried out to test the Brazilian theory.

"Following the admission of Brazilian regulator Anvisa that it did not test Sputnik V vaccine, Sputnik V is undertaking a legal defamation proceeding in Brazil against Anvisa for knowingly spreading false and inaccurate information," it said.

"Anvisa made incorrect and misleading statements without having tested the actual Sputnik V vaccine."

Comments

Comments are closed for this article.